Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Girish Mallesara

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Asia-Pacific Journal of Clinical Oncology|January 31, 2025
Efficacy and Safety of Four Weeks of Moderately Hypofractionated Chemoradiation for Unresectable, Stage 3 Non-Small Cell Lung Cancer: A Systematic ReviewJoanna Jane Ludbrook, Mahesh Kumar, Yu Yang Soon, et al.
British Journal of Cancer|March 10, 2017
Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancerHui-Ming Lin, Kate L Mahon, Calan Spielman, et al.
Asia-Pacific Journal of Clinical Oncology|March 21, 2024
Esophageal chemoradiotherapy with concurrent nivolumab: Pilot results in the palliative treatment of oligometastatic diseaseFiona Day, Swetha Sridharan, Catherine Johnson, et al.
BMC Cancer|December 17, 2022
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)Fiona Day, Swetha Sridharan, James Lynam, et al.
The Prostate|March 28, 2024
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancerKate L Mahon, Sarah Im Sutherland, Hui Ming Lin, et al.
Therapeutic Advances in Medical Oncology|March 6, 2023
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)Louise Emmett, Nikeith John, Sarennya Pathmanandavel, et al.
International Journal of Cancer|July 26, 2017
A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancerHui-Ming Lin, Kate L Mahon, Jacquelyn M Weir, et al.
Internal Medicine Journal|May 28, 2021
Business as unusual: medical oncology services adapt and deliver during COVID-19Avraham Travers, Kim Adler, Gillian Blanchard, et al.
Nature Medicine|October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J Luke, Manish R Patel, George R Blumenschein, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Asia-Pacific Journal of Clinical Oncology|January 31, 2025
Efficacy and Safety of Four Weeks of Moderately Hypofractionated Chemoradiation for Unresectable, Stage 3 Non-Small Cell Lung Cancer: A Systematic ReviewJoanna Jane Ludbrook, Mahesh Kumar, Yu Yang Soon, et al.
British Journal of Cancer|March 10, 2017
Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancerHui-Ming Lin, Kate L Mahon, Calan Spielman, et al.
Asia-Pacific Journal of Clinical Oncology|March 21, 2024
Esophageal chemoradiotherapy with concurrent nivolumab: Pilot results in the palliative treatment of oligometastatic diseaseFiona Day, Swetha Sridharan, Catherine Johnson, et al.
BMC Cancer|December 17, 2022
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)Fiona Day, Swetha Sridharan, James Lynam, et al.
The Prostate|March 28, 2024
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancerKate L Mahon, Sarah Im Sutherland, Hui Ming Lin, et al.
Therapeutic Advances in Medical Oncology|March 6, 2023
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)Louise Emmett, Nikeith John, Sarennya Pathmanandavel, et al.
International Journal of Cancer|July 26, 2017
A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancerHui-Ming Lin, Kate L Mahon, Jacquelyn M Weir, et al.
Internal Medicine Journal|May 28, 2021
Business as unusual: medical oncology services adapt and deliver during COVID-19Avraham Travers, Kim Adler, Gillian Blanchard, et al.
Nature Medicine|October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J Luke, Manish R Patel, George R Blumenschein, et al.
Pageof 1